

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Medigene Limited	10/01/2008
RECEIVING PARTY DATA	
Name:	Immunocore Limited
Street Address:	57c Milton Park
Internal Address:	Abingdon
City:	Oxfordshire
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RX
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12603255
CORRESPONDENCE DATA	
Fax Number:	(212)407-7799
Phone:	212 407-7700
Email:	ipdocketny@vedderprice.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Thomas J. Kowalski
Address Line 1:	1633 Broadway
Address Line 2:	Vedder Price P.C.
Address Line 4:	New York, NEW YORK 10019
ATTORNEY DOCKET NUMBER:	44172.00.2009
NAME OF SUBMITTER:	Sarah Marciano
Total Attachments: 12 source=2009MedigenetolImmunocore#page1.tif	

CH \$40.00 12603255

source=2009MedigenetolImmunocore#page2.tif
source=2009MedigenetolImmunocore#page3.tif
source=2009MedigenetolImmunocore#page4.tif
source=2009MedigenetolImmunocore#page5.tif
source=2009MedigenetolImmunocore#page6.tif
source=2009MedigenetolImmunocore#page7.tif
source=2009MedigenetolImmunocore#page8.tif
source=2009MedigenetolImmunocore#page9.tif
source=2009MedigenetolImmunocore#page10.tif
source=2009MedigenetolImmunocore#page11.tif
source=2009MedigenetolImmunocore#page12.tif

MEDIGENE LIMITED (1)

- AND -

IMMUNOCORE LIMITED (2)

DEED OF ASSIGNMENT OF PATENTS

Lovells
Atlantic House
Holborn Viaduct
London
EC1A 2FG
Ref: CM3/SAK/DAL
T1663.00250

DEED OF ASSIGNMENT OF PATENTS

THIS DEED OF ASSIGNMENT is made

1 October

2008

BETWEEN

- (1) **Medigene Limited** (formerly known as Avidex Limited) a company registered in England and Wales with company number 3740304 whose registered office is at 57c Milton Park, Abingdon, Oxfordshire, OX14 4RX (the "**Assignor**"); and
- (2) **Immunocore Limited** a company registered in England and Wales with company number 6456207 whose registered office is at 9400 Garsington Road, Oxford Business Park, Oxford, OX4 2HN (the "**Assignee**").

WHEREAS

- (A) The Assignor is registered, either in its previous name of Avidex Limited or its current name of Medigene Limited, as the owner of the patents and patent applications and is the owner of certain inventions and/or interests in such patents and patent applications, as set out in Clause 1 below.
- (B) The Assignee acquired certain of the assets of the Assignor under a Business Sale Agreement between the parties of even date.
- (C) The Assignor has agreed to assign, transfer and convey to the Assignee all right, title and interest in and to the Patents (as defined below).

IT IS AGREED:

1. **ASSIGNMENT**

The Assignor does hereby assign, transfer and convey to the Assignee with full title guarantee all right, title, interest and benefit in and to: (i) the patents and patent applications listed in Schedule "A" hereto; (ii) all patent applications and patents arising from any of the patents or patent applications in (i) or which claim priority from or common priority with or which form the basis of priority for any of the patents or patent applications in (i); and (iii) any renewals, extensions (including supplementary protection certificates), continuations, or divisional applications deriving from any of the patents or patent applications in (i) or (ii) and any other similar rights relating thereto (the "**Patents**"); together with any rights of action in relation to any of the Patents including the right to sue for damages and other remedies in respect of any previous infringements thereof or any acts prior to the date hereof, together with the right to apply for, prosecute and obtain patent protection throughout the world in respect of the inventions claimed or described in any of the Patents including the right to claim priority therefrom.

2. **FURTHER ASSURANCE**

At the Assignee's reasonable request, the Assignor covenants with the Assignee (at the Assignor's cost) to execute all such documents and provide all such assistance (or where applicable to procure the execution of such documents or the provision of such assistance) as may be necessary to ensure that the Assignee obtains the full benefit of the assignments set out above and to perfect the Assignee's title to any and all of the rights in and to the Patents and to enable the Assignee to register in any country the transfer of those rights to it.

3. **NO WARRANTIES**

To the extent legally permissible in any relevant jurisdiction in relation to this Deed, the parties exclude all terms and conditions (including warranties) that may be implied into this Deed by operation of law, except for those implied by the full title guarantee. The parties agree that the provisions of this Deed (including all documents entered into pursuant to this Deed) are fair and reasonable.

4. **CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999**

No person who is not a party to this Deed may enforce any term of this Deed by virtue of the Contracts (Rights of Third Parties) Act 1999.

5. **GOVERNING LAW**

This Assignment is subject to and shall be construed in accordance with English law and the parties hereby submit to the non-exclusive jurisdiction of the English Courts.

IN WITNESS WHEREOF the parties have executed and delivered this Deed the day and year first above written:


IN WITNESS WHEREOF the parties have executed and delivered this Deed the day and year first written above:

Executed as a Deed by
MEDIGENE LIMITED
acting by a director

)
)
)



in the presence of:


Witness Signature

CHRISTIAN MATERN
Witness Name

BRITISH
Witness Address

81379 Minden, Germany
Witness Address

Executed as a Deed by
IMMUNOCORE LIMITED
acting by a director

)
)
)

in the presence of:

.....
Witness Signature

.....
Witness Name

3. **NO WARRANTIES**

To the extent legally permissible in any relevant jurisdiction in relation to this Deed, the parties exclude all terms and conditions (including warranties) that may be implied into this Deed by operation of law, except for those implied by the full title guarantee. The parties agree that the provisions of this Deed (including all documents entered into pursuant to this Deed) are fair and reasonable.

4. **CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999**

No person who is not a party to this Deed may enforce any term of this Deed by virtue of the Contracts (Rights of Third Parties) Act 1999.

5. **GOVERNING LAW**

This Assignment is subject to and shall be construed in accordance with English law and the parties hereby submit to the non-exclusive jurisdiction of the English Courts.

IN WITNESS WHEREOF the parties have executed and delivered this Deed the day and year first above written:

IN WITNESS WHEREOF the parties have executed and delivered this Deed the day and year first written above:

Executed as a Deed by
MEDIGENE LIMITED
acting by a director

in the presence of:

.....
Witness Signature

.....
Witness Name

.....
Witness Address

Executed as a Deed by
IMMUNOCORE LIMITED
acting by a director

in the presence of:

.....
Witness Signature

TRACEY MILES
Witness Name

Jasmine Cottage
Bicester Road
Lewerton OX26 5DP.

JASMINE COTTAGE

21 CESTER ROAD LAUNTON OX26 5DP

Witness Address

LIB02/CM3SAK/2260579.3

Lovells

1.1 Invention "Monoclonal TCRs" (Case 14)

Title of PCT application: Soluble T Cell Receptor

<i>Territory</i>	<i>Application No.</i>
GB	0121187.9 (abandoned)
GB	0219146.8 (abandoned)
US	60/404182 (abandoned)
PCT	PCT/GB02/03986
AU	2002321581
CA	2457652
CN	02819279.6
EA	200400384
EP	02755287.6
IL	160359
IN	00647/CHENP/2004
HK	04109015.8
JP	2003-525033
KR	10-2004-7003158
MX	PA/a/2004/001974
NO	2004 1325
NZ	531208
PL	P368980
SG	200400713.4
US	US 10/486924
US(Cont)	US 11/926,480
US (Div)	US 11/926,391
ZA	2004/1197

1.2 Invention "CD1-binding MTCRs" (Case 30)

Title of PCT application: Modified T cell Receptor

<i>Territory</i>	<i>Application No.</i>
GB	0304068.0 (abandoned)
PCT	PCT/GB03/02986
US	10/544,448
EP	03815958.8
JP	2004-568435
CN	03826014.X
CA	2516702
AU	2003254443
NZ	541596
ZA	2005/06516
(CN) HK	06109937.1

1.3 Invention "Single chain MTCRs" (Case 18)

Title of PCT application: Single chain recombinant T cell receptors

<i>Territory</i>	<i>Application No.</i>
GB	0223399.7 (abandoned)
PCT	PCT/GB2003/04310
AU	2003271904
CA	2501870
CN	200380101143.1
EP	03753742.0
JP	2005-500992

IL	167652
IN	854/CHENP/2005
NO	2005/2198
NZ	539225
RU	2005114004
US	10/530035
ZA	2005/02927

1.4 Invention "MTCR Adoptive Therapy" (Case 58)

Title of PCT application: Cells expressing a modified T cell receptor

<i>Territory</i>	<i>Application No.</i>
GB	0414499.4 (abandoned)
GB	0421831.9 (abandoned)
GB	0511123.2 (abandoned)
PCT	PCT/GB2005/002570
EP	05756424.7
JP	2007-518692
US	11/597,252

1.5 Invention "TCR Display" (Case 19)

Title of PCT application: T cell receptor display

<i>Territory</i>	<i>Application No.</i>
GB	0226227.7 (abandoned)
PCT	PCT/GB2003/04636
AU	2003276403
CA	2505558
CN	200380102928.0
EP	03811009.4
JP	2005-506662
IL	167745
IN	1176/CHENP/2005
NO	20052743
NZ	539226
RU	2005117971
US	10/532,879
ZA	2005/03336

1.6 Invention "High Affinity CDR2 Mutant TCRs" (Case 53)

Title of PCT application: Method of improving T cell receptors

<i>Territory</i>	<i>Application No.</i>
GB	0411125.8 (abandoned)
GB	0419646.5 (abandoned)
PCT	PCT/GB2005/001781
AU	2005246073
CA	2,567,349
CN	200580015878.1
CN(HK)	07111256.9
EP	05741949.1
JP	2007-517396
NZ	550815
US	11/579,874
ZA	2006/09462

1.7 Invention "High Affinity NY-ESO TCRs" (Case 52)

Title of PCT application: High Affinity NY-ESO TCRs

<i>Territory</i>	<i>Application No.</i>
GB	0411123.3 (abandoned)
GB	0419643.2 (abandoned)
PCT	PCT/GB2005/001924
AU	2005245664
CA	2,566,363
CN	200580016449.6
EP	05745017.3
JP	2007-517414
NZ	550810
US	11/596,458
ZA	2006/09461

1.8 **Invention "High Affinity Telomerase TCRs" (Case 55)**

Title of PCT application: High Affinity Telomerase TCRs

<i>Territory</i>	<i>Application No.</i>
GB	0411772.7 (abandoned)
GB	0419644.0 (abandoned)
PCT	PCT/GB2005/000970
EP	05718025.9
US	11/597,244
JP	2007-514064

1.9 **Invention "PEGylated TCRs " (Case 20)**

Title of PCT application: Receptors

<i>Territory</i>	<i>Application No.</i>
GB	0228112.9 (abandoned)
PCT	PCT/GB2003/05104
EP	03777006.2
US	10/535965
JP	2004-570696

1.10 **Invention "High Affinity Melan-A TCRs" (Case 77)**

Title of PCT application: High affinity Melan-A T cell receptors

<i>Territory</i>	<i>Application No.</i>
GB	0511124.0 (abandoned)
PCT	PCT/GB2006/001980
US	11/915,766
EP	06744042.0
JP	2008-514187
AU	2006253941
BR	P10611326-5
CA	2,610,786
CN	200680019562.4
EA	200702677
IN	3/CHENP/2008
MX	MX/a/2007/014919
ZA	2007/10009

1.11 **Invention "High Affinity HIV Gag TCRs" (Case 74)**

Title of PCT application: High affinity HIV T cell receptors

<i>Territory</i>	<i>Application No.</i>
GB	0506760.8 (abandoned)

GB	0516487.6 (abandoned)
PCT	PCT/GB2006/001147
US	11/887,536
EP	06726555.3
JP	2008-503585
AU	2006228308
CA	2,602,463
CN	200680011470.1
NZ	561338
ZA	2007/08037

1.12 Invention "NY-ESO TCR DNA" (Case 90)
Title of PCT application: NY-ESO TCR DNA

<i>Territory</i>	<i>Application No.</i>
PCT	PCT/GB2006/003649

1.13 Invention "TCR Adoptive Therapy" (Case 91)
Title of PCT application: T Cell Therapies

<i>Territory</i>	<i>Application No.</i>
PCT	PCT/GB2007/003676

1.14 Invention "TCR Adoptive Therapy" (Case 106)
Title of PCT application: Modified T cell receptors and related materials and methods

<i>Territory</i>	<i>Application No.</i>
PCT	PCT/US2007/79487

1.15 Invention "VYG HLA-A24 Telomerase TCRs" (Case 82)
Title of PCT application: Isolated T cells receptors which specifically bind to VYGFVRACL-HLA-24

<i>Territory</i>	<i>Application No.</i>
GB	0524477.7 (abandoned)
PCT	PCT/GB2006/001857
EP	06727144.5
US	11/915,190
JP	2008-512901
CN	200680018255.4

1.16 Invention "Allergy TCRs" (Case 101)
Title of GB application: T cell receptor-based hypersensitivity therapeutics

<i>Territory</i>	<i>Application No.</i>
GB	0801910.1

1.17 Invention "Allergy TCRs 2 (Non-neutralising)" (Case 102)
Title of GB application: T cell receptor-based hypersensitivity therapeutics

<i>Territory</i>	<i>Application No.</i>
GB	0801911.9

1.18 Invention "Specific Binding Member (SBM) associations" (Case 103)

Title of GB application: Bifunctional Proteinaceous complexes

Territory Application No.
GB 0801912.7

- 1.19 Invention "Cellular pMHC Assay" (Case 104)**
Title of GB application: Cellular peptide-MHC Assay

Territory Application No.
GB 0804032.1

- 1.20 Invention "High Affinity CD8 T cell adoptive therapy" (Case 105)**
Title of GB application: T cells presenting modified CD8

Territory Application No.
GB 0806238.2

- 1.21 Invention "High Affinity gp100 TCRs" (Case 107)**
Title of GB application: High Affinity gp100 T cell receptors

Territory Application No.
GB 0812380.4

- 1.22 Invention "Soluble "Zippered" TCRs " (Case 2)**
Title of PCT application: Soluble T Cell Receptor

Territory Application No.
GB 9810759.2 (abandoned)
GB 9821129.5 (abandoned)
PCT PCT/GB99/01588
EP 99922360.5
JP 2000-549728

- 1.23 Invention "Diabetes T cell receptors" (Case 108)**
Title of GB application: "Diabetes T cell receptors"

Territory Application No.
GB 0816096.2

- 1.24 Invention "Modified anti-CD3 antibodies" (Case 109)**
GB Patent application yet to be filed

